Brief: Nxera Pharma Receives $10 Mln From Abbvie
27/06/2024 01:16
June 26 (Reuters) - Nxera Pharma Co Ltd 4565.T :
* NXERA PHARMA RECEIVES US$10 MILLION FROM ABBVIE AS
COLLABORATION
TARGETING NEUROLOGICAL DISEASES ACHIEVES FIRST RESEARCH AND
DEVELOPMENT MILESTONE
* NXERA PHARMA RECEIVES US$10 MILLION FROM ABBVIE AS
COLLABORATION
TARGETING NEUROLOGICAL DISEASES ACHIEVES FIRST RESEARCH AND
DEVELOPMENT MILESTONE
Source text for Eikon: ID:nGNX4gHjgK
Further company coverage: 4565.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up